| Autor: |
Özge KAMA BAŞCI, Ferhat EKİNCİ, Gonca AKDERE ATEŞ, Atike Pinar ERDOĞAN, Ahmet DİRİCAN |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Contemporary Medicine. 12:1033-1035 |
| ISSN: |
2667-7180 |
| DOI: |
10.16899/jcm.1175879 |
| Popis: |
Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There is no series with many patients on the use of enzalutamide in patients with end-stage renal disease (ESRD). We present a patient diagnosed with mCRPC who was followed up with enzalutamide treatment for about 5 years after progression with docetaxel and who was on hemodialysis 3 days a week. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
